Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.71 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.68 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | QPCT | Q16769 | 1/20 | 0.62 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.62 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL411704 | 0.98 | CYP19A1 (0.69) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL6030852 | 0.95 | HMOX1 (0.71) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL227437 | 0.94 | CYP19A1 (0.63) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL230077 | 0.94 | CYP19A1 (0.63) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL12045329 | 0.93 | HMOX1 (0.69) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL9996042 | 0.93 | HMOX1 (0.69) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL9996078 | 0.92 | HMOX1 (0.68) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL409741 | 0.89 | HMOX1 (0.72) | CYP19A1TBXAS1HMOX1CYP1A2POLB | |
| SCHEMBL7868470 | 0.88 | QPCT (0.59) | CYP19A1TBXAS1HMOX1QPCT | |
| Hydrochloric Acid SCHEMBL7527357 | 0.87 | HMOX1 (0.70) | CYP19A1TBXAS1HMOX1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112908530-B | Power distribution copper core wire and wire core stranding device | 芜湖森普铁芯有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-107427758-A | Utilize the separation of ion liquid solvent | 切弗朗菲利浦化学公司 | 2017-12-01 | — | — | CN | claimed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| CN-117986553-A | Thermotropic liquid crystal polyester compound and preparation method thereof | 无锡学院 | 2024-05-07 | — | — | CN | disclosed |
| CN-115064758-A | Preparation method of lithium battery with strong stability | 江西永德立新能源有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-111419840-B | Application of candesartan cilexetil or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/or treating novel coronavirus pneumonia | 中山大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-112409265-A | Diamine monomer containing bisoxazole unit and preparation method thereof | 东华大学 | 2021-02-26 | — | — | CN | disclosed |
| EP-3687978-A1 | PARA-PHENYLENEDIAMINE BASES WITH CATIONIC HETEROCYCLES, AND THE USE OF SAME FOR OXIDATION DYEING KERATIN FIBRES | L'Oreal (FR) | 2020-08-05 | — | — | EP | disclosed |
| WO-2020152206-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
| CN-109844069-A | Utilize isobutane alkylation oil plant amylene | 雪佛龙美国公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109642165-A | Integrated coalescing system for separating liquid hydrocarbons from dispersed ionic liquid | 雪佛龙美国公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| CN-1415741-A | Resistance gene of benzimidazole applied in chaetomium | YANG QIAN (CN) | 2003-05-07 | — | — | CN | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
| US-5569655-A | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 614/4885TBXAS1 1257/4885HMOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.